In re Gabapentin Patent Litigation, 503 F.3d 1254 (Fed. Cir. 2007)

Prior to joining Ross Aronstam & Moritz, Ben Schladweiler represented Pfizer as part of an appellate team that successfully reversed a summary judgment of noninfringement in litigation concerning the blockbuster drug Neurontin®. The U.S. Court of Appeals for the Federal Circuit upheld Pfizer’s claim construction and ruled that the district court erred in determining that there were no genuine issues of material fact concerning whether Pfizer met its burden of proving infringement.